Efficacy of daclatasvir in hepatitis C virus

References

• Ghany MG, Strader DB, Thomas DL, Seef LB. American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009;49:1335-74
   PubMed Web of Science ®Google Scholar
• Seef LB. Natural history of chronic hepatitis C. Hepatology 2002;36:S35-46
   PubMed Web of Science ®Google Scholar
• Kiyosawa K, Sodeyama T, Tanaka E, et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology 1990;12:671-5
   PubMed Web of Science ®Google Scholar
• Namiki I, Nishiguchi S, Hino K, et al. Management of hepatitis C; Report of the Consensus Meeting at the 45th annual meeting of the Japan Society of Hepatology (2009). Hepatol Res 2010;40:347-68
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Hanada K, Mizokami M, et al. A comparison of the molecular clock of hepatitis C virus in the United States and Japan predicts that hepatocellular carcinoma incidence in the United States will increase over the next two decades. Proc Natl Acad Sci USA 2002;99:11584-9
   Web of Science ®Google Scholar
• Bruno S, Stroffolini T, Colombo M, et al. Sustained virological response to IFN-α is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 2007;45:579-87
   PubMed Web of Science ®Google Scholar
• Veldt BJ, Heathcote EJ, Wedemeyer H, et al. Sustaiend virological response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007;147:677-84
   PubMed Web of Science ®Google Scholar
• Manns MP, HcHutchson JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C; a randomized trial. Lancet 2001;358:958-65
   PubMed Web of Science ®Google Scholar
• Fried MW, Schiffmann ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavrin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82
   PubMed Web of Science ®Google Scholar
• Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364:2405-16
   PubMed Web of Science ®Google Scholar
• Poordad FJr, McCone J, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1195-206
   PubMed Web of Science ®Google Scholar
• Akuta N, Suzuki F, Seko Y, et al. Determinants of response to triple therapy of telaprevir, peginterferon, and ribavirin in previous non-responders infected with HCV genotype 1. J Med Virol 2012;84:1097-105
   PubMed Web of Science ®Google Scholar
• Gao M. Antiviral activity and resistance of HCV NS5A replication complex inhibitors. Curr Opin Virol 2013;3:514-20
   PubMed Web of Science ®Google Scholar
• Nettles RE, Gao M, Bifano M, et al. Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1. Hepatology 2011;54:1956-65
   PubMed Web of Science ®Google Scholar
• Asahina Y, Izumi M, Umeda N, et al. Pharmakokinetics and enhanced PKR response in patients with chronic hepatitis C treated with pegylated interferon alpha-2b and ribavirin. J Viral Hepat 2007;14:396-403
   PubMed Web of Science ®Google Scholar
• Honda M, Sakai A, Yomashita T, Hokuriku Liver Study Group. Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology 2010;139:499-509
   PubMed Web of Science ®Google Scholar
• Izumi N, Yokosuka O, Kawada N, et al. Daclatasvir conbined with peginterferon alfa-2a and ribavirn in Japanese patients infected with hepatitis C genotype 1. Antivir Ther 2014. [Epub ahead of print]
   Web of Science ®Google Scholar
• Suzuki F, Toyota J, Ikeda K, et al. A randomized trial of daclatasvir with peginteerferon alfa-2b and ribavirin for HCV genotype 1 infection. Antivir Ther 2014. [Epub ahead of print]
   Web of Science ®Google Scholar
• McPhee F, Hernandez D, Zhou N, et al. HCV genotype 1-infected patients receiving daclatasvir plus ribavirin and peginterferon alfa-2a or 2b. Antiviral Ther 2014. [Epub ahead of print]
   Web of Science ®Google Scholar
• McPhee F, Hernandez D, Yu F, et al. Resistance analysis of hepatitis C virus genotype 1 prior treatment null responder receiving daclatasvir and asunaprevir. Hepatology 2013;58:902-11
   PubMed Web of Science ®Google Scholar
• Lok AS, Gardiner DF, Hezode C, et al. Randomized trial of daclatasvir and asunaprevir with or without Peg IFN/RBV for hepatitis C virus genotype 1 null responders. J Hepatol 2014;60:490-9
   PubMed Web of Science ®Google Scholar
• Sulkowski MS, Gardiner DF, Rodriguez-Torres M, AI444040 Study Group. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014;370:211-21
   PubMed Web of Science ®Google Scholar
• Dore GJ, Lawitz E, Hezole C, et al. Daclatasvir combined with peginterferon alfa-2a and ribavirin for 12 or 16 weeks in patients with HCV genotype 2 or 3 infection: COMMAND GT2/3 study. J Hepatol 2013;58:S570-1
   Web of Science ®Google Scholar
• Cahyama K, Takahashi S, Toyota J, et al. Dual therapy with the nonstuructual protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatology 2012;55:742-8
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Ikeda K, Suzuki F, et al. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. J Hepatol 2013;58:655-62
   PubMed Web of Science ®Google Scholar
• Karino Y, Toyota J, Ikeda F, et al. Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivarals daclatasvir and asunaprevir. J Hepatol 2013;58:646-54
   PubMed Web of Science ®Google Scholar
• Kumada H, Suzuki Y, Ikeda K, et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology 2014;59(6):2083-91
   PubMed Web of Science ®Google Scholar
• Wang C, Huang H, Valera L, et al. Hepatitis C virus RNA elimination and development of resistance in replicon cells treated with BMS-790052. Antimicrob Agents Chemother 2012;56:1350-8
   PubMed Web of Science ®Google Scholar
• Suzuki F, Sezaki H, Akuta N, et al. Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b. J Clin Virol 2012;54:352-4
   PubMed Web of Science ®Google Scholar
• Everson GT, Sims KD, Rodriguez-Torres M, et al. Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naïve patients with HCV genotype 1 infection. Gastroenterology 2014;146:420-9
   PubMed Web of Science ®Google Scholar
• Nakamoto S, Kanda T, Wu S, et al. Hepatitis C virus NS5A inhibitors and drug resistance mutations. World J Gastroenterol 2014;20:2902-12
   PubMed Web of Science ®Google Scholar